Performing Direct Ophthalmoscopy

DJ Haeussler, Jr, MS, DVM, DACVO
The Animal Eye Institute
Cincinnati, Ohio

An ophthalmoscopic (or fundoscopic) examination evaluates the interior surface of the eye, known as the fundus, and can be accomplished using indirect lenses, a panoptic, or a direct ophthalmoscope. Various lenses can be used for indirect ophthalmoscopy, which gives the examiner a broader picture of the fundus. A panoptic is a useful instrument that can be used to view the fundus, has a larger field of view than the direct ophthalmoscope, and provides a larger working distance from the patient to the examiner. The direct ophthalmoscope provides an upright, unreversed image that is magnified approximately 15 times when the examiner and patient both have normal focused vision (ie, not myopic or hyperopic).
A direct ophthalmoscope allows the examiner to view the optic nerve head (or disc), tapetum lucidum, nontapetum, and retinal vessels by shining a light through the pupil of the eye (see Glossary, page 45); however, it provides only a limited view of the fundus and further evaluation may be required when abnormalities are present. A direct ophthalmoscope is useful when examining depth of lesions within the fundus, as well as obtaining accurate measurements of lesions using the overlying grid feature.

The ophthalmoscope can be useful for diagnosing optic neuritis, chronic glaucoma, and retinal detachments, tears, and degeneration. If a more panoramic view of the retina is desired, such as looking at large retinal lesions or detachments, the examiner should favor an indirect lens. Patient cooperation is essential during examination, and close physical contact between the veterinarian and the patient is required. This article describes how to use a direct ophthalmoscope to examine the fundus.

**What is a Direct Ophthalmoscope?**

A direct ophthalmoscope is a handheld illuminated instrument, typically with a handle that also serves as the battery pack. (See Figure 1.) Many units are rechargeable and portable. The head of the direct ophthalmoscope contains a light source, lenses, filters, and a viewing aperture. The handle can be rotated to turn the light on and off and also acts as a rheostat for adjusting the light intensity. The lenses allow the examiner to correct for refractive error of the user and the patient. The appropriate lens strength is selected by turning the wheel on either side of the instrument head clockwise to increase the green/positive diopter to focus on structures that are close or counterclockwise to increase the red/negative diopter to focus on structures that are far.

The depth and elevation of lesions can be estimated based on the difference between the diopters needed to focus on the lesions and normal structures. Most direct ophthalmoscopes provide a blue light that can be used to examine the cornea for abrasions and ulcers after fluorescein staining. Multiple apertures
Patient cooperation is essential during examination, and close physical contact between the veterinarian and the patient is required.

(i.e., small, medium, large, half) facilitate evaluation of different sized pupils. For example, the small aperture can be used in a bright room when the patient’s pupil is constricted, while the large aperture is appropriate to view a pupil dilated using a mydriatic eyedrop. When a cataract is present, the half aperture allows the examiner to focus on the unobscured portion of the pupil. Many direct ophthalmoscopes also have a slit beam for examining aqueous flare and depth of corneal lesions and an illuminated grid that allows the examiner to measure lesion size.

Steps for Performing Direct Ophthalmoscopy

1. Examine the patient’s pupillary light reflexes, menace responses, and dazzle reflexes, and ensure that the patient has normal intraocular pressures. If no abnormalities are detected, administer 1 drop of tropicamide in each eye and wait 20 minutes for the pupils to dilate.

2. Escort the patient to a dim-to-dark room and place on the examination table, if possible. The examiner’s and the patient’s eyes should be at the same level, so consider sitting on a stool that faces the patient with the examiner sitting directly in front of the patient. If the patient is too large to safely restrain on the table, the examination can be performed with the patient on the floor. A team member should gently but firmly hold the patient’s head to keep it as still as possible during examination.

3. Position the ophthalmoscope so it is resting on the examiner’s brow and the patient’s eye is approximately 25 to 30 cm away from the examiner’s eyes. (See Figure 2.) The direct ophthalmoscope should be in the hand lateral to the patient’s eye that is being examined. For instance, if the examiner is examining a patient’s right eye, the direct ophthalmoscope should be in the examiner’s left hand and he or she should open the patient’s eyelids with the right hand. The light should be set to a dim setting and gradually increased for better visualization. The lens should be set to a 0 diopter. Then, evaluate the pupil and tapetal reflexes and lens clarity, and locate the tapetal reflection. Slowly move to within 2 to 4 cm of the patient’s eye. (See Figure 3.)
4 Locate and focus on the optic nerve head by slowly adjusting the lenses using the focusing wheel to select the appropriate positive or negative diopter. Examine the optic nerve head carefully, and document its color, margins, and shape. Blurry edges suggest peripapillary edema and are consistent with optic neuritis. (See Figure 4.) Examine and document depth of the cup. A depression greater than normal may suggest damage from chronic glaucoma.

5 Examine the tapetum lucidum and document its color. Hyperreflection (i.e., increased reflectivity associated with thinning of the tapetum) suggests degeneration or progressive retinal atrophy, whereas hyporeflection (i.e., decreased reflectivity associated with the addition of a substance under the retina) suggests subretinal edema or infiltration of cells (i.e., bacterial, fungal, neoplastic). Note the presence of subretinal, preretinal, and intraretinal hemorrhages and obvious retinal detachments or tears. (See Figure 5.)

6 Examine and document the nontapetum. Areas of depigmentation indicate choroidal hypoplasia, uveodermatologic syndrome, and variation of normal in some breeds. Note the presence of subretinal, preretinal, and intraretinal hemorrhages and obvious retinal detachments or tears.
Examine and document the retinal vessels. Increased vessel caliber and tortuosity suggest systemic hypertension or hyperviscosity syndrome. Decreased vessel caliber, number, and tortuosity suggest retinal degeneration. (See Figure 6.)

Conclusion
A direct ophthalmoscope provides a magnified image of the fundus, which can aid in the diagnosis of diseases and conditions of the interior surface of the eye. When used in conjunction with fluorescein staining, a direct ophthalmoscope can facilitate examination of the cornea and identify corneal lesion depth and aqueous flare. The direct ophthalmoscope provides only a limited view of the fundus and patient cooperation is very important. Knowing the instrument’s abilities and limitations will greatly enhance the results of the examination.

GLOSSARY

- **FUNDUS**: Posterior aspect of the globe composed of the retina, choroid, optic nerve head, and sclera.
- **NONTAPETUM**: Pigmented ventral portion of the fundus not associated with the tapetum.
- **OPTIC NERVE**: Second cranial nerve responsible for transmitting light and impulses responsible for vision to the brain.
- **RETINA**: Structure located between the most posterior aspect of the vitreous and anterior to the choroid responsible for the neurotransmission of visual stimuli.
- **TAPETUM LUCIDUM**: Highly reflective structure found in many domestic species associated with the choroid in the dorsal aspect of the fundus and responsible for the amplification of light.

COMING SOON!
FROM NOR BROOK®...
LOXICOM® ORAL SUSPENSION
2 X 100 ML SIZE

Contact your veterinary products distributor or Norbrook, Inc. at (888) 705-0408 for information and availability.

- Contains the same active ingredient as Metacam® (meloxicam) Oral Suspension
- Reduces your dispensing costs across all weight ranges of dogs

See page 46 for product information summary.
Loxicom®
(meloxicam oral suspension)
1.5 mg/mL Oral Suspension
Non-steroidal anti-inflammatory drug for oral use in dogs only

Warning: Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats. See Contraindications, Warnings, and Precautions for detailed information.

Brief Summary: Before using Loxicom Oral Suspension, consult the product insert, a summary of which follows.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Description: Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class.

Indications: Loxicom Oral Suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

Contraindications: Dogs with known hypersensitivity to meloxicam should not receive Loxicom Oral Suspension. Do not use Loxicom Oral Suspension in cats. Acute renal failure and death have been associated with the use of meloxicam in cats.

Warnings: Not for use in humans. Keep this and all medications out of reach of children. Consult a veterinarian in case of accidental ingestion by humans. For oral use in dogs only. As with any NSAID all dogs should undergo a thorough history and physical examination before the initiation of NSAID therapy. Appropriate laboratory testing to establish hematological and serum biochemical baseline data is recommended prior to and periodically during administration. To report suspected adverse reactions, to obtain a Safety Data Sheet, or for technical assistance, call Norbrook at 1-866-591-5777.

Precautions: The safe use of Loxicom Oral Suspension in dogs younger than 6 months of age, dogs used for breeding, or in pregnant or lactating dogs has not been evaluated. As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached. NSAIDs may inhibit the prostaglandins that maintain normal hemodynamic and/or renal function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed. Since NSAIDs possess the potential to induce gastrointestinal ulcerations and/or perforations, concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided or closely monitored. The use of concomitantly protein-bound drugs with Loxicom Oral Suspension has not been studied in dogs. Commonly used protein-bound drugs include cardiac, anticonvulsant and behavioral medications. The influence of concomitant drugs that may inhibit metabolism of Loxicom Oral Suspension has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy.

Adverse Reactions: Field safety was evaluated in 306 dogs. Based on the results of two studies, GI abnormalities (vomiting, soft stools, diarrhea, and inappetence) were the most common adverse reactions associated with the administration of meloxicam. Of the dogs that took meloxicam (n=157), forty experienced vomiting, nineteen experienced diarrhea/soft stool, five experienced inappetence, and one each experienced bloody stool, bleeding gums after dental procedure, lethargy/swollen corpus, and epiphora. Of the dogs that took the placebo (n=148), twenty-three experienced vomiting, eleven experienced diarrhea/soft stool, and one experienced inappetence. In foreign suspected adverse reaction drug reporting (SADR) reporting over a 9 year period, incidences of adverse reactions related to meloxicam administration included: auto-immune hemolytic anemia (1 dog), thrombocytopenia (1 dog), polyarthritis (1 dog), nursing puppy lethargy (1 dog), and pyoderma (1 dog).

Effectiveness: The effectiveness of meloxicam was demonstrated in two field studies involving a total of 277 dogs representing various breeds, between six months and sixteen years of age, all diagnosed with osteoarthritis. Both of the placebo-controlled, masked studies were conducted for 14 days. All dogs received 0.2 mg/kg on day 1. All dogs were maintained on 0.1 mg/kg oral meloxicam from days 2 through 14 of both studies. Parameters evaluated by veterinarians included lameness, weight-bearing, pain on palpation, and overall improvement. Parameters assessed by owners included mobility, ability to rise, limping, and overall improvement. In the first study (n=109), dogs showed clinical improvement with statistical significance after 14 days of meloxicam treatment for all parameters. In the second study (n=46), dogs receiving meloxicam showed a clinical improvement after 14 days of therapy for all parameters; however, statistical significance was demonstrated only for the overall investigator evaluation on day 7, and for the owner evaluation on day 14.

How Supplied: Loxicom Oral Suspension 1.5 mg/mL: 10, 32 and 100 mL bottles with small and large dosing syringes.

Storage: Store at controlled room temperature 68-77°F (20-25°C).

Exclusions permitted between 59°F and 88°F (15°C and 30°C). Brief exposure to temperature up to 104°F (40°C) may be tolerated provided the mean kinetic temperature does not exceed 77°F (25°C); however such exposure should be minimized.

Made in the UK.
Manufactured by: Norbrook Laboratories Limited
Newry, BT33 6PU, Co. Down, Northern Ireland

Loxicom® is a registered trademark of Norbrook Laboratories Limited.